$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

$bpth Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-K Financial Statement

#000114420418018611 Filed on April 02, 2018

Income Statement

Concept	2016 Q4	2016	2015 Q4
Revenue	$13.00K	$13.00K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$730.0K	$3.010M	$590.0K
YoY Change	23.73%	22.36%	-32.18%
% of Gross Profit
Research & Development	$950.0K	$5.474M	$870.0K
YoY Change	9.2%	81.26%	-46.64%
% of Gross Profit
Depreciation & Amortization	$50.00K	$43.00K	$50.00K
YoY Change	0.0%	4.88%	0.0%
% of Gross Profit
Operating Expenses	$1.681M	$8.488M	$1.463M
YoY Change	14.9%	54.75%	-8.74%
Operating Profit	-$1.668M	-$8.475M	-$1.463M
YoY Change	14.01%	54.53%	-8.74%
Interest Expense	$0.00	$10.00K	$0.00
YoY Change		-50.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$297.0K	$1.725M	$5.000K
YoY Change	5840.0%	9483.33%	-4.58%
Pretax Income	-$1.370M	-$6.750M	-$1.460M
YoY Change	-6.16%	23.47%	-8.75%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.371M	-$6.750M	-$1.458M
YoY Change	-5.97%	23.47%	-8.75%
Net Earnings / Revenue	-10546.15%	-51923.08%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.854M	-$14.67M	-$3.244M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.380M	$9.380M	$8.850M
YoY Change	5.99%	5.99%	-36.15%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$902.0K	$1.280M	$179.0K
YoY Change	403.91%	72.97%	78.12%
Inventory
Prepaid Expenses	$376.0K		$560.0K
Receivables
Other Receivables
Total Short-Term Assets	$10.65M	$10.65M	$9.593M
YoY Change	11.05%	11.05%	-32.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$614.0K	$610.0K	$72.00K
YoY Change	752.78%	771.43%	-36.35%
Goodwill
YoY Change
Intangibles	$929.0K		$1.090M
YoY Change	-14.77%		-12.86%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.543M	$1.550M	$1.162M
YoY Change	32.79%	32.48%	-14.81%
TOTAL ASSETS
Total Short-Term Assets	$10.65M	$10.65M	$9.593M
Total Long-Term Assets	$1.543M	$1.550M	$1.162M
Total Assets	$12.20M	$12.20M	$10.76M
YoY Change	13.4%	13.38%	-30.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$69.00K	$70.00K	$54.00K
YoY Change	27.78%	40.0%	31.62%
Accrued Expenses	$969.0K	$970.0K	$883.0K
YoY Change	9.74%	10.23%	248.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.050M	$1.050M	$937.0K
YoY Change	12.06%	11.7%	66.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.910M	$2.910M
YoY Change
Total Long-Term Liabilities	$2.910M	$2.910M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.050M	$1.050M	$937.0K
Total Long-Term Liabilities	$2.910M	$2.910M	$0.00
Total Liabilities	$3.956M	$3.960M	$937.0K
YoY Change	322.2%	321.28%	66.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.13M		-$25.38M
YoY Change	26.59%		27.45%
Common Stock	$96.00K		$90.00K
YoY Change	6.67%		0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.240M	$8.240M	$9.818M
YoY Change
Total Liabilities & Shareholders Equity	$12.20M	$12.20M	$10.76M
YoY Change	13.4%	13.38%	-30.51%

Cashflow Statement

Concept	2016 Q4	2016	2015 Q4
OPERATING ACTIVITIES
Net Income	-$1.371M	-$6.750M	-$1.458M
YoY Change	-5.97%	23.47%	-8.75%
Depreciation, Depletion And Amortization	$50.00K	$43.00K	$50.00K
YoY Change	0.0%	4.88%	0.0%
Cash From Operating Activities	-$1.610M	-$8.148M	-$1.000M
YoY Change	61.0%	62.96%	-13.79%
INVESTING ACTIVITIES
Capital Expenditures	-$310.0K	$338.0K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$310.0K	-$338.0K	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$9.007M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$9.007M	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-1.610M	-$8.148M	-1.000M
Cash From Investing Activities	-310.0K	-$338.0K	0.000
Cash From Financing Activities	0.000	$9.007M	0.000
Net Change In Cash	-1.920M	$521.0K	-1.000M
YoY Change	92.0%	-110.42%	29.87%
FREE CASH FLOW
Cash From Operating Activities	-$1.610M	-$8.148M	-$1.000M
Capital Expenditures	-$310.0K	$338.0K	$0.00
Free Cash Flow	-$1.300M	-$8.486M	-$1.000M
YoY Change	30.0%	69.72%	-9.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2906000	USD
CY2017Q4	us-gaap	Cash Cash	5965000	USD
CY2016Q4	us-gaap	Cash Cash	9375000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1117000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	376000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	353000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	902000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	7435000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	10653000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	984000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	708000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	330000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	94000	USD
CY2017Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500000	USD
CY2016Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1731000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1571000	USD
CY2017Q4	us-gaap	Assets Assets	8858000	USD
CY2016Q4	us-gaap	Assets Assets	12196000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	52000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	69000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	739000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	969000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39157000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32134000	USD
CY2017	us-gaap	Revenues Revenues	37000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5480000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3523000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	9000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1943000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-7023000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.8
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10081000	shares
CY2016	us-gaap	Revenues Revenues	13000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5474000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-8475000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1725000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-6750000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9270000	shares
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2374000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1713000	USD
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	161000	USD
CY2016	us-gaap	Depreciation Depreciation	43000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-184000	USD
CY2016	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	723000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-146000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8148000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9007000	USD
CY2016	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	521000	USD
CY2015Q4	us-gaap	Cash Cash	8854000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	338000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-338000	USD
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	160000	USD
CY2017	us-gaap	Depreciation Depreciation	251000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	741000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-549000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7957000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5085000	USD
CY2017	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-3410000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	538000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-538000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1518000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	793000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	784000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	247000	USD
CY2016Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	588235	shares
CY2016Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	9300000	USD
CY2016Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	900000	USD
CY2016Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	2500000	USD
CY2017	bpth	Research And Development Costs Expenses ResearchAndDevelopmentCostsExpenses	5500000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	562041	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	544167	shares
CY2017Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	100000	USD
CY2016Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	100000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	100000	USD
CY2017Q4	bpth	Accrued Vacation And Bonus AccruedVacationAndBonus	100000	USD
CY2017Q4	bpth	Accrued Clinical And Preclinical AccruedClinicalAndPreclinical	400000	USD
CY2017Q4	bpth	Accrued License Maintenance Fee AccruedLicenseMaintenanceFee	100000	USD
CY2016Q4	bpth	Accrued Vacation And Bonus AccruedVacationAndBonus	400000	USD
CY2016Q4	bpth	Accrued Clinical And Preclinical AccruedClinicalAndPreclinical	200000	USD
CY2016Q4	bpth	Accrued License Maintenance Fee AccruedLicenseMaintenanceFee	100000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	100000	USD
CY2016Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	2900000	USD
CY2017	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	2400000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-2374000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	4619000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1713000	USD
CY2016Q3	bpth	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	10000000	USD
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	588235	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.00
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.90
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0137	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.09	pure
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0206	pure
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	900000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	800000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y3M18D
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	800000	USD
CY2017Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	47000	USD
CY2017	bpth	Research And Development Tax Credit Carryforward Expiration Period ResearchAndDevelopmentTaxCreditCarryforwardExpirationPeriod	P2028Y
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	654000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7516000	USD
CY2016Q4	bpth	Deferred Tax Assets Technology Licenses DeferredTaxAssetsTechnologyLicenses	60000	USD
CY2017Q4	bpth	Deferred Tax Assets Technology Licenses DeferredTaxAssetsTechnologyLicenses	36000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1259000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1542000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	443000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	387000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10969000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9518000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10965000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9518000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	bpth	Deferred Tax Asset Accrued Vacation DeferredTaxAssetAccruedVacation	32000	USD
CY2017Q4	bpth	Deferred Tax Asset Accrued Vacation DeferredTaxAssetAccruedVacation	17000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	9000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	4000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	5000	USD
CY2015	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	3000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	5000	USD
CY2016	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	6000	USD
CY2015	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	0	USD
CY2017	bpth	Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant	658000	USD
CY2016	bpth	Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant	582000	USD
CY2015	bpth	Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrant	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	614000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	769000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	929000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11339	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11339	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9564	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9564	shares
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-440000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	1038000	USD
CY2016	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8061000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6750000	USD
CY2017	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	175000	USD
CY2016	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	9818000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	793000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	784000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4388000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	175000	USD
CY2017	bpth	Adjustments To Additional Paid In Capital Deemed Dividend AdjustmentsToAdditionalPaidInCapitalDeemedDividend	-1038000	USD
CY2017	bpth	Adjustments To Additional Paid In Capital Warrant Exercise Price Modification AdjustmentsToAdditionalPaidInCapitalWarrantExercisePriceModification	1038000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3567000	USD
CY2017Q2	bpth	Classofwarrantorrightexercisablenumber Classofwarrantorrightexercisablenumber	441176	shares
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	15000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2017	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-252000	USD
CY2016Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	48000	USD
CY2017	us-gaap	General Discussion Of Pension And Other Postretirement Benefits GeneralDiscussionOfPensionAndOtherPostretirementBenefits	We make matching contributions equal to 100% of the first 3% and 50% of the next 2% of each employee’s base salary up to the allowable amount which is fully vested on the date the matching contributions are made.
CY2017Q4	us-gaap	Prepaid Insurance PrepaidInsurance	100000	USD
CY2018Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10
CY2016Q4	bpth	Accrued Laboratory Expense AccruedLaboratoryExpense	200000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	116000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	61000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	177000	USD
CY2017	bpth	Stock Issue During Period Value Warrants Exercised StockIssueDuringPeriodValueWarrantsExercised	1518000	USD
CY2017Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1100000	USD
CY2017Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	1200000	USD
CY2016Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	4600000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2906000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-357000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-175000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1278000	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y6M
CY2017	bpth	Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Option Outstanding Weighted Average Exercise Price Per Share SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionOutstandingWeightedAverageExercisePricePerShare	7.70
CY2017Q4	bpth	Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableNumberOfShares	1262000	shares
CY2017	bpth	Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Weighted Average Exercise Price Per Share SharebasedCompensationArrangementBySharebasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePricePerShare	7.80
CY2017Q2	bpth	Class Of Warrant Or Right Exercised Number ClassOfWarrantOrRightExercisedNumber	11176	shares
CY2017Q2	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1500000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3567000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9007000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1447000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3001000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1899000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4937000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	USD
CY2015	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	USD
CY2017	bpth	Warrants Transferred To Equity Upon Modification WarrantsTransferredToEquityUponModification	797000	USD
CY2016	bpth	Warrants Transferred To Equity Upon Modification WarrantsTransferredToEquityUponModification	0	USD
CY2017	bpth	Adjustments To Additional Paid In Capital Warrants Transferred To Equity Upon Modification AdjustmentsToAdditionalPaidInCapitalWarrantsTransferredToEquityUponModification	797000	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></i><strong>Concentration of Credit Risk</strong></b> Financial instruments that potentially subject us to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the “FDIC”) up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font>. As a result, as of December 31, 2017, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.7</font> million of our cash balances was not covered by the FDIC. As of December 31, 2016 we had approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.4</font> million in cash on-hand, of which approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.1</font> million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></i></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Use of Estimates </i></b> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“U.S.”) requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends as well as on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company’s estimates. These estimates include accrued clinical trial costs, stock-based compensation expense, valuation of warrants and valuation of deferred tax assets.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	4900000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9500000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11000000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	bpth	Research And Development Costs Expenses ResearchAndDevelopmentCostsExpenses	5500000	USD
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	400000	USD
CY2017Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0	USD
CY2016	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	1700000	USD

Files In Submission

Name	View Source	Status
0001144204-18-018611-index-headers.html	Edgar Link	pending
0001144204-18-018611-index.html	Edgar Link	pending
0001144204-18-018611.txt	Edgar Link	pending
0001144204-18-018611-xbrl.zip	Edgar Link	pending
bpth-20171231.xml	Edgar Link	completed
bpth-20171231.xsd	Edgar Link	pending
bpth-20171231_cal.xml	Edgar Link	unprocessable
bpth-20171231_def.xml	Edgar Link	unprocessable
bpth-20171231_lab.xml	Edgar Link	unprocessable
bpth-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv488319_10k.htm	Edgar Link	pending
tv488319_ex21-1.htm	Edgar Link	pending
tv488319_ex23-1.htm	Edgar Link	pending
tv488319_ex31.htm	Edgar Link	pending
tv488319_ex32.htm	Edgar Link	pending
tv488319_ex4-9.htm	Edgar Link	pending
tv488319_img1.jpg	Edgar Link	pending
tv488319_img10.jpg	Edgar Link	pending
tv488319_img11.jpg	Edgar Link	pending
tv488319_img12.jpg	Edgar Link	pending
tv488319_img13.jpg	Edgar Link	pending
tv488319_img2.jpg	Edgar Link	pending
tv488319_img3.jpg	Edgar Link	pending
tv488319_img4.jpg	Edgar Link	pending
tv488319_img5.jpg	Edgar Link	pending
tv488319_img6.jpg	Edgar Link	pending
tv488319_img7.jpg	Edgar Link	pending
tv488319_img8.jpg	Edgar Link	pending
tv488319_img9.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

2016 Q4 Form 10-K Financial Statement

#000114420418018611 Filed on April 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH BIO-PATH HOLDINGS, INC. Stock $bpth

2016 Q4 Form 10-K Financial Statement

#000114420418018611 Filed on April 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth